Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in
hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker
has been validated in multiple studies.
Objectives: This is a prospective cross-sectional study considering the association between FGF23
and bioimpedance-measured volume overload in hemodialysis patients.
Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end
of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before
Results: The results indicated no significant correlation between mean serum FGF23 levels and
volume overload in hemodialysis patients (P=0.824).
Conclusion: Although this study did not show any association between volume overload and FGF23,
further studies are needed to define the role of FGF23 as a volume overload marker.